Formula (I): [wherein XYZ represents N-CO-NR4AR4B and the like, R1 represents phenyl and the like, R2A and R2B are the same or different and represent a hydrogen atom and the like, R3A to R3D And R6 are the same or different and each represents a hydrogen atom, R4A and R4B are the same or different, each represents aryl or the like, and n represents 1 or 2, or a pharmaceutically acceptable compound thereof. It has a strong α7 nicotinic acetylcholine receptor (α7 nAChR) regulatory action, including an acceptable salt, and is a cholinergic disorder of the central nervous system (CNS) and / or peripheral nervous system (PNS), smooth muscle contraction Providing therapeutic drugs for diseases related to diseases, endocrine diseases, and diseases related to neurodegeneration.式（Ｉ）：［式中、Ｘ－Ｙ－ＺはＮ－ＣＯ－ＮＲ４ＡＲ４Ｂ等を表し、Ｒ１はフェニル等を表し、Ｒ２Ａ及びＲ２Ｂは、同一又は異なって、水素原子等を表し、Ｒ３Ａ～Ｒ３Ｄ及びＲ６は、同一又は異なって、水素原子等を表し、Ｒ４Ａ及びＲ４Ｂは、同一又は異なって、アリール等を表し、ｎは、１又は２を表す］で表される化合物又はその製薬学的に許容される塩を含む、強いα７ニコチン性アセチルコリン受容体（α７ ｎＡＣｈＲ）の調節作用を有し、中枢神経系（ＣＮＳ）及び／又は末梢神経系（ＰＮＳ）のコリン作動性に関する疾患、平滑筋収縮に関する疾患、内分泌疾患、神経変性に関する疾患等の治療薬の提供。
